Madrigal Pharmaceuticals Company Description

Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of non-alcoholic steatohepatitis (NASH) in the United States.

Its lead product candidate is resmetirom, a liver-directed thyroid hormone receptor beta agonist, which is in Phase 3 clinical trials for treating NASH.

The company is headquartered in West Conshohocken, Pennsylvania.

Madrigal Pharmaceuticals, Inc.

Country	United States
Industry	Pharmaceutical Preparations
Employees	376
CEO	William Sibold

Contact Details

Address: Four Tower Bridge West Conshohocken, Delaware 19428 United States
Phone	267 824 2827
Website	madrigalpharma.com

Stock Details

Ticker Symbol	0JXI
Exchange	London Stock Exchange
Stock Type	Common Stock
Fiscal Year	January - December
Reporting Currency	USD
SIC Code	2834

Key Executives

Name	Position
William Sibold	Chief Executive Officer
Mardi Dier	Chief Financial Officer
Mark Underwood	Chief Operating Officer
Tina Ventura	Head of Investor Relations